Navigation Links
iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies
Date:7/29/2009

Establishes New Throughput Standard in Cardiac Core Lab Industry

Rochester, NY (PRWEB) July 29, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced that it has processed a total of 45 million cardiac cycles for agency facing studies in a single month utilizing the company's Highly Automated QT(sm) method. The total volume of data represents the same number of cardiac cycles as would traditionally be evaluated in approximately one thousand TQT studies.

"We are enthusiastic about our continued string of industry firsts," said Sasha Latypova, Executive Vice President. "Our clients are gaining significant benefits from our advanced ECG methods, rapid turnaround times and highly scalable core lab processing capacity to meet their drug development needs."

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision and high cost of the "gold standard" manual QT measurements has lead to efforts toward automating QT interval measurement.

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/1000tqt/cardiacsafety/prweb2672624.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. iCardiac Selected by Top 10 Pharmaceutical Company
2. iCardiac Selected for Multiple Cardiac Safety Studies
3. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
4. iCardiac Reports Significant Revenue Growth and Profitability
5. Varian Medical Systems to Showcase a Wide Spectrum of New and Updated Products That Improve Radiotherapy Treatment Processes at 2009 AAPM Meeting
6. Bion Announces Approval of New U.S. Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes
7. Event Alert: SPL R4 Compliance and its Impact on Regulatory Submission Processes
8. Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes
9. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
10. Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site
11. Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):